What’s Trending: ADCs: Pipelines, Products & CDMO Growth 

Sponsored by Lonza AG

Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments, and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights.  

Gaurav Chaudhary, CEO, Roots Analysis

DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance. ICYMI, other recent episodes include:  

“Drug Launches & Approvals in 2025: The Blockbuster Contenders” featuring Matthew Arnold, Principal Analyst and Content Strategist, Clarivate  

“CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?” featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice;  

“Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?” featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)  

“Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?” featuring Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate  

“Biomanufacturing: How are Industry Capacity & Supply Chains Trending?” featuring Eric Langer, MBA, Managing Partner & President, BioPlan Associates, and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates;   

“Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?”  featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice; and   

“Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead” featuring Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP.  

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

You May Also Like

Drug Launches & Approvals in 2025: The Blockbuster Contenders

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 

By
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important…

Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty? 

By
As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and…